<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03075267</url>
  </required_header>
  <id_info>
    <org_study_id>PT010010</org_study_id>
    <nct_id>NCT03075267</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind, Parallel-Group, Study to Assess the Pharmacokinetics and Safety of Two Doses of PT010 and a Single Dose of PT003 in Healthy Chinese Adult Subjects Following A Single Administrations and After Chronic Administration for 7 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess the pharmacokinetics and safety of two doses of PT010 and a single dose of
      PT003 in healthy Chinese adult subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Randomized, Double-Blind, Parallel Group, Study to Assess the Pharmacokinetics and
      Safety of Two Doses of PT010 and a Single Dose of PT003 in Healthy Chinese Adult Subjects
      Following a Single Administration and After Chronic Administration for 7 Days
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 17, 2017</start_date>
  <completion_date type="Actual">September 5, 2017</completion_date>
  <primary_completion_date type="Actual">September 5, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Day 1 and Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from 0-12 hours (AUC0-12)</measure>
    <time_frame>Day 1 and Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum plasma concentration (tmax)</measure>
    <time_frame>Day 1 and Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from 0 to the time of the last measurable plasma concentration (AUC 0-t)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from 0 extrapolated to infinity (AUC0-inf)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination half-life (t½)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total body clearance (CL/F)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution (Vd/F)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination rate constant (λz)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation ratio for Cmax (RAC [Cmax])</measure>
    <time_frame>Day 1 and Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation ratio for AUC0-12 (RAC [AUC0-12])</measure>
    <time_frame>Day 1 and Day 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal findings in physical examination</measure>
    <time_frame>Day -1 and Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in laboratory tests</measure>
    <time_frame>Day -1 and Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in electrocardiogram</measure>
    <time_frame>Day -1 and Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant adverse events</measure>
    <time_frame>Day 1 through Day 12-14</time_frame>
    <description>(Day -28 through Day 12-14, only for randomized subjects)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in vital signs</measure>
    <time_frame>Day -1 and Day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>PT010 (BGF MDI) 320/14.4/9.6 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumurate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT010 (BGF MDI) 160/14.4/9.6 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT010 (BGF MDI) 160/14.4/9.6 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT003 (GFF MDI) 14.4/9.6 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT003 (GFF MDI) 14.4/9.6 µg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT010 (BGF MDI) 320/14.4/9.6 µg</intervention_name>
    <description>A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.</description>
    <arm_group_label>PT010 (BGF MDI) 320/14.4/9.6 µg</arm_group_label>
    <other_name>Budesonide, Glycopyrronium, Formoterol Metered Dose Inhaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT010 (BGF MDI) 160/14.4/9.6 µg</intervention_name>
    <description>A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.</description>
    <arm_group_label>PT010 (BGF MDI) 160/14.4/9.6 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT003 (GFF MDI) 14.4/9.6 µg</intervention_name>
    <description>A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.</description>
    <arm_group_label>PT003 (GFF MDI) 14.4/9.6 µg</arm_group_label>
    <other_name>Glycopyrronium and Formoterol Fumurate Metered Dose Inhaler</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female Chinese subjects 18-45 years of age

          -  Females of childbearing potential must agree to be abstinent or else use one of the
             following medically acceptable forms of contraception A female whose male partner has
             had a vasectomy must agree to use one additional form of medically acceptable
             contraception.

        A male subject with female partner of child bearing potential must agree to use one
        additional form of medically acceptable contraception

        -Be in good general health as assessed at Screening and have no clinically significant
        abnormal labs at Screening .

        Exclusion Criteria:

          -  Pregnant or nursing female subjects or subjects who are trying to conceive

          -  Subjects with clinically significant neurologic, cardiovascular, hepatic, renal,
             endocrinologic, pulmonary, hematological, psychiatric, or other medical illness that
             would interfere with participation in this study;

          -  Subjects with a history of ECG abnormalities

          -  Subjects who have cancer that has not been in complete remission for at least 5 years;

          -  Male subjects with symptomatic prostatic hypertrophy that is clinically significant in
             the opinion of the Investigator;

          -  Male subjects with a trans-urethral resection of the prostate or full resection of the
             prostate within 6 months prior to Screening;

          -  Males with bladder neck obstruction or urinary retention that is clinically
             significant in the opinion of the Investigator;

          -  Subjects with a diagnosis of glaucoma that in the opinion of the Investigator has not
             been adequately treated;

          -  History of substance-related disorders within 1 year of Screening;

          -  History of smoking or the use of nicotine containing products or electronic cigarettes
             within 3 months of Screening by self-reporting;

          -  A positive alcohol breathalyzer or urine drug screen for drugs of abuse at the
             Screening Visit or at the beginning of each inpatient period;

          -  Treatment with any prescription or non-prescription drugs (including vitamins, herbal,
             and dietary supplements) within 30 days

          -  Positivity for human immunodeficiency virus (HIV) or Hepatitis B surface antigen
             (HbsAg) or positive hepatitis C antibody at Screening

          -  Positive for Syphilis Antibody

          -  Subjects with any flu-like syndrome or other respiratory infections

          -  Recently vaccinated with an attenuated live virus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul M. Dorinsky, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pearl Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Xuhui District Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>March 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2017</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

